CAJ | 학술논문

目的：评估紫杉醇脂质体和替吉奥联合治疗晚期胃癌的有效性和安全性。方法：选取符合研究标准的晚期胃癌患者61例（研究组30例，对照组31例），分别给予紫杉醇脂质体联合替吉奥或多西他赛＋顺铂＋氟尿嘧啶化疗方案（DCF）4个周期进行治疗，观察2组患者的客观疗效、无进展生存期和毒副反应。结果：研究组与对照组治疗的反应率（36．67％vs 45．16％；χ2＝0．455，P＝0．500）、控制率（86．67％ vs 87．10％；χ2＜0．001，P＞0．999）差异均无统计意义，但中位无进展生存时间（32周 vs 24周；χ2＝4．701，P＝0．030）、白细胞减少（80．00％ vs 96．77％；χ2＝4．223，P＝0．040）和贫血（70．00％vs 93．55％；χ2＝5．720，P＝0．017）的发生率差异均有统计学意义。结论：紫杉醇脂质体联合替吉奥化疗方案与DCF化疗方案疗效相当，但毒副反应明显减少。
목적：평고자삼순지질체화체길오연합치료만기위암적유효성화안전성。방법：선취부합연구표준적만기위암환자61례（연구조30례，대조조31례），분별급여자삼순지질체연합체길오혹다서타새＋순박＋불뇨밀정화료방안（DCF）4개주기진행치료，관찰2조환자적객관료효、무진전생존기화독부반응。결과：연구조여대조조치료적반응솔（36．67％vs 45．16％；χ2＝0．455，P＝0．500）、공제솔（86．67％ vs 87．10％；χ2＜0．001，P＞0．999）차이균무통계의의，단중위무진전생존시간（32주 vs 24주；χ2＝4．701，P＝0．030）、백세포감소（80．00％ vs 96．77％；χ2＝4．223，P＝0．040）화빈혈（70．00％vs 93．55％；χ2＝5．720，P＝0．017）적발생솔차이균유통계학의의。결론：자삼순지질체연합체길오화료방안여DCF화료방안료효상당，단독부반응명현감소。
Aim:To evaluate the efficacy and safety of paclitaxel liposome combined Gimeracil and Oteracil Porassium capsules(S-1) treating advanced gastric cancer .Methods:The patients with advanced gastric cancer were selected by the study criteria and randomly assigned docetaxel +cisplatin+fluorouracil ( DCF) chemotherapy or paclitaxel liposome com-bined with S-1 4 cycles of treatment .The curative effect with objective , progression free survival and toxicity were observed in these two groups .Results:The baseline data had no statistically significant difference .Compared with control group , the treatment response rate (36.67%vs 45.16%;χ2 =0.455, P=0.500) and control rate (86.67% vs 87.10%;χ2 <0.001,P>0.999) of treatment group had no statistically significant difference , but the median PFS (32 weeks vs 24 weeks;χ2 =4.701, P =0.030), leukopenia (80.00% vs 96.77%;χ2 =4.223,P =0.040), anemia (70.00% vs 93.55%;χ2 =5.720,P=0.017) had statistical significance .Conclusion: Compared with DCF chemotherapy , paclitaxel liposome combined with S-1 chemotherapy can obtain the same effect and less toxicity .